INFIQ 股息： Infinity Pharmaceuticals Inc 收益洞察

Q: Infinity Pharmaceuticals Inc 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Infinity Pharmaceuticals Inc 的总资产为 $42，净损失为 $-44

Q: INFIQ 的关键财务比率是什么？

Infinity Pharmaceuticals Inc 的流动比率是 0.68，净利 margin 为 -2,200，每股销售为 $0.02。

Q: Infinity Pharmaceuticals Inc 的收入按细分市场或地理位置如何划分？

当前 Infinity Pharmaceuticals Inc 数据不可用。

Q: Infinity Pharmaceuticals Inc 是否盈利？

不，根据最新的财务报表，Infinity Pharmaceuticals Inc 的净损失为 $-44

Q: Infinity Pharmaceuticals Inc 有负债吗？

是的，Infinity Pharmaceuticals Inc 的负债为 61

Q: Infinity Pharmaceuticals Inc 的流通股有多少？

Infinity Pharmaceuticals Inc 的总流通股为 89.4

主页

股票

INFIQ

INFIQ 财务

Infinity Pharmaceuticals Inc

收盘价：Jan 16, 16:00:00 GMT-5

盘后：Jan 16, 20:00:00 GMT-5

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

INFIQ 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
营收	2	2	1	1	3	22
营收同比增长 (YoY)	0%	100%	0%	-67%	-86%	267%
营收成本	1	1	1	1	7	0
毛利润	1	1	0	0	-4	22
销售、一般及管理费用	16	13	14	12	14	14
研发	27	32	31	26	27	19
营业费用	43	45	45	39	41	34
其他非经营性收入 (费用)	--	--	--	--	--	0
税前利润	-40	-44	-45	-40	-47	-11
所得税费用	--	--	--	0	0	0
净利润	-40	-44	-45	-40	-47	-11
净利润增长	-13%	-2%	13%	-15%	327%	-73%
稀释后流通股数	89.9	89.2	85.6	59.9	57	55.4
股份同比变动 (YoY)	1%	4%	43%	5%	3%	9%
每股收益 (摊薄)	-0.45	-0.5	-0.53	-0.68	-0.83	-0.2
每股收益增长率	-13%	-6%	-22%	-18%	315%	-76%
自由现金流	-38	-42	-40	-35	-43	-4
每股自由现金流	--	--	--	--	--	--
毛利率	50%	50%	0%	0%	-133.33%	100%
营业利润率	-2,100%	-2,200%	-4,500%	-3,800%	-1,500%	-50%
净利率	-2,000%	-2,200%	-4,500%	-4,000%	-1,566.66%	-50%
自由现金流利润率	-1,900%	-2,100%	-4,000%	-3,500%	-1,433.33%	-18.18%
EBITDA	-42	-44	-45	-38	-45	-11
EBITDA 利润率	-2,100%	-2,200%	-4,500%	-3,800%	-1,500%	-50%
EBITDA 中的折旧与摊销	0	0	0	0	0	0
EBIT	-42	-44	-45	-38	-45	-11
EBIT 利润率	-2,100%	-2,200%	-4,500%	-3,800%	-1,500%	-50%
有效税率	--	--	--	0%	0%	0%

Follow-Up Questions

Infinity Pharmaceuticals Inc 的关键财务报表是什么？



INFIQ 的关键财务比率是什么？



Infinity Pharmaceuticals Inc 的收入按细分市场或地理位置如何划分？



Infinity Pharmaceuticals Inc 是否盈利？



Infinity Pharmaceuticals Inc 有负债吗？



Infinity Pharmaceuticals Inc 的流通股有多少？



关键数据

前收盘价

$0.0001

开盘价

当日区间

$0 - $0.0001

52周范围

$0 - $0.0001

交易量

109.4K

平均成交量

每股收益（TTM）

-0.46

股息收益率

市值

$9.0K

什么是 INFIQ？

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing novel medicines for people with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2000-07-27. The firm is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

功能特性

交易策略